Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Equity Average (2016 - 2025)

Historic Equity Average for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $7.4 million.

  • China Pharma Holdings' Equity Average rose 601.98% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year increase of 601.98%. This contributed to the annual value of $7.6 million for FY2024, which is 2944.25% up from last year.
  • As of Q3 2025, China Pharma Holdings' Equity Average stood at $7.4 million, which was up 601.98% from $6.7 million recorded in Q2 2025.
  • Over the past 5 years, China Pharma Holdings' Equity Average peaked at $7.9 million during Q1 2024, and registered a low of $3.4 million during Q3 2022.
  • Over the past 5 years, China Pharma Holdings' median Equity Average value was $6.7 million (recorded in 2025), while the average stood at $6.2 million.
  • In the last 5 years, China Pharma Holdings' Equity Average crashed by 4873.01% in 2022 and then surged by 9039.5% in 2023.
  • Over the past 5 years, China Pharma Holdings' Equity Average (Quarter) stood at $6.4 million in 2021, then plummeted by 44.65% to $3.6 million in 2022, then skyrocketed by 90.39% to $6.8 million in 2023, then grew by 5.24% to $7.1 million in 2024, then rose by 3.5% to $7.4 million in 2025.
  • Its last three reported values are $7.4 million in Q3 2025, $6.7 million for Q2 2025, and $7.4 million during Q1 2025.